{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:52:52Z","timestamp":1787068372464,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune thrombocytopenia (ITP) is an autoimmune condition often managed with corticosteroids, intravenous immunoglobulins, or thrombopoietin receptor agonists. In settings where these therapies are inaccessible or contraindicated, dapsone an older antimicrobial agent with immunomodulatory effects has been proposed as an alternative, though its comparative effectiveness and safety profile remain inadequately defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study systematically reviews and synthesizes existing data to assess the efficacy and tolerability of dapsone in adult patients with ITP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following PRISMA guidelines, a literature search across PubMed, Embase, and Cochrane databases identified observational studies and interventional trials evaluating dapsone in ITP, including comparisons with standard treatments. Primary outcomes included complete and overall response rates, hemoglobin variation, relapse frequency, and adverse effects. Risk of bias was evaluated using the Newcastle\u2013Ottawa Scale and Cochrane tools. Meta-analysis was conducted using RevMan and R (meta\/metafor).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four eligible studies encompassing over 270 patients were analyzed. The pooled complete response rate was 28%, while the overall response rate reached 47%. Dapsone use was associated with a modest decline in hemoglobin levels with a mean decrease of 1.74\u00a0g\/dL, and relapse occurred in approximately 21% of patients. Adverse effects most commonly hemolytic anemia and methemoglobinemia were reported in 18% of patients, though generally not severe. Heterogeneity was explored through leave-one-out sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dapsone demonstrates moderate efficacy and an acceptable safety profile in adult ITP patients, especially in resource-limited contexts. While it may not match thrombopoietin agonists in preventing relapse, its low cost and oral administration offer practical advantages. Further large-scale randomized trials are warranted to clarify its role in ITP management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40001-025-03427-0","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T13:54:49Z","timestamp":1765461289000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of dapsone in adult immune thrombocytopenia: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"31","author":[{"given":"Iftikhar","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soban Ali","family":"Qasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shree","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris","family":"Mumtaz Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sozen","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Aleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hammad","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Omar","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Ahtisham","family":"Halim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil Ahmad","family":"Kamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"issue":"3","key":"3427_CR1","doi-asserted-by":"publisher","first-page":"e1003583","DOI":"10.1371\/journal.pmed.1003583","volume":"18","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021;18(3):e1003583. https:\/\/doi.org\/10.1371\/journal.pmed.1003583.","journal-title":"PLoS Med"},{"issue":"03","key":"3427_CR2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1055\/s-0039-1700512","volume":"46","author":"H Al-Samkari","year":"2020","unstructured":"Al-Samkari H, Kuter DJ. Immune thrombocytopenia in adults: modern approaches to diagnosis and treatment. Semin Thromb Hemost. 2020;46(03):275\u201388. https:\/\/doi.org\/10.1055\/s-0039-1700512.","journal-title":"Semin Thromb Hemost"},{"issue":"11","key":"3427_CR3","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1111\/jth.12371","volume":"11","author":"C Rodrigo","year":"2013","unstructured":"Rodrigo C, Gooneratne L. Dapsone for primary immune thrombocytopenia in adults and children: an evidence\u2010based review. J Thromb Haemost. 2013;11(11):1946\u201353. https:\/\/doi.org\/10.1111\/jth.12371.","journal-title":"J Thromb Haemost"},{"issue":"8","key":"3427_CR4","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1182\/bloodadvances.2024014939","volume":"9","author":"M Larue","year":"2025","unstructured":"Larue M, Moulis G, Rueter M, Audia S, Comont T, Terriou L, et al. Efficacy and safety of dapsone in adult primary immune thrombocytopenia. Blood Adv. 2025;9(8):1976\u201383. https:\/\/doi.org\/10.1182\/bloodadvances.2024014939.","journal-title":"Blood Adv"},{"issue":"23","key":"3427_CR5","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829\u201366. https:\/\/doi.org\/10.1182\/bloodadvances.2019000966.","journal-title":"Blood Adv"},{"issue":"1","key":"3427_CR6","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1182\/hematology.2024000594","volume":"2024","author":"W Ghanima","year":"2024","unstructured":"Ghanima W, Cuker A, Michel M. Insights on treatment of adult ITP: algorithm for management and role of multimodal therapy. Hematol Am Soc Hematol Educ Program. 2024;2024(1):678\u201384. https:\/\/doi.org\/10.1182\/hematology.2024000594.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"22","key":"3427_CR7","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","volume":"3","author":"D Provan","year":"2019","unstructured":"Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780\u2013817. https:\/\/doi.org\/10.1182\/bloodadvances.2019000812.","journal-title":"Blood Adv"},{"issue":"2","key":"3427_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.5045\/br.2017.52.2.95","volume":"52","author":"JY Lee","year":"2017","unstructured":"Lee JY, Lee J-O, Jung JY, Bang S-M. Dapsone therapy for refractory immune thrombocytopenia patients: a case series. Blood Res. 2017;52(2):95\u20139.","journal-title":"Blood Res"},{"issue":"2","key":"3427_CR9","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/cber.190804102131","volume":"41","author":"E Fromm","year":"1908","unstructured":"Fromm E, Wittmann J. Derivate des p-Nitrothiophenols. Ber Dtsch Chem Ges. 1908;41(2):2264\u201373.","journal-title":"Ber Dtsch Chem Ges"},{"issue":"1","key":"3427_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1445-5994.2000.tb01075.x","volume":"30","author":"R Lush","year":"2000","unstructured":"Lush R, Iland H, Peat B, Young G. Successful use of dapsone in refractory pregnancy-associated idiopathic thrombocytopenic purpura. Aust N Z J Med. 2000;30(1):105\u20137. https:\/\/doi.org\/10.1111\/j.1445-5994.2000.tb01075.x.","journal-title":"Aust N Z J Med"},{"issue":"5","key":"3427_CR11","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jval.2016.03.1856","volume":"19","author":"R Allen","year":"2016","unstructured":"Allen R, Bryden P, Grotzinger KM, Stapelkamp C, Woods B. Cost-effectiveness of Eltrombopag versus Romiplostim for the treatment of chronic immune thrombocytopenia in England and Wales. Value Health. 2016;19(5):614\u201322.","journal-title":"Value Health"},{"key":"3427_CR12","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.5. 2024. (updated August 2024). www.trainingcochraneorg\/handbook.2024. Accessed 12 May 2025."},{"issue":"9","key":"3427_CR13","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1111\/jth.15396","volume":"19","author":"MP Colella","year":"2021","unstructured":"Colella MP, Orsi FA, Alves ECF, Delmoro GF, Yamaguti-Hayakawa GG, de Paula EV, et al. A retrospective analysis of 122 immune thrombocytopenia patients treated with dapsone: efficacy, safety and factors associated with treatment response. J Thromb Haemost. 2021;19(9):2275\u201386. https:\/\/doi.org\/10.1111\/jth.15396.","journal-title":"J Thromb Haemost"},{"key":"3427_CR14","first-page":"421","volume":"49","author":"T Dutta","year":"2001","unstructured":"Dutta T, Goel A, Ghotekar L, Hamide A, Badhe B, Basu D. Dapsone in treatment of chronic idiopathic thrombocytopenic purpura in adults. J Assoc Physicians India. 2001;49:421\u20135.","journal-title":"J Assoc Physicians India"},{"issue":"10","key":"3427_CR15","doi-asserted-by":"publisher","first-page":"e0187296","DOI":"10.1371\/journal.pone.0187296","volume":"12","author":"C Est\u00e8ve","year":"2017","unstructured":"Est\u00e8ve C, Samson M, Guilhem A, Nicolas B, Leguy-Seguin V, Berthier S, et al. Efficacy and safety of dapsone as second line therapy for adult immune thrombocytopenia: a retrospective study of 42 patients. PLoS ONE. 2017;12(10):e0187296. https:\/\/doi.org\/10.1371\/journal.pone.0187296.","journal-title":"PLoS ONE"},{"issue":"3","key":"3427_CR16","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/bjh.19277","volume":"204","author":"N Bharadwaj","year":"2024","unstructured":"Bharadwaj N, Munireddy J, Selvam S, Bharadwaj V, Prakash A. Dapsone for paediatric chronic immune thrombocytopenia: short report from a tertiary centre in South India. Br J Haematol. 2024;204(3):1024\u20138. https:\/\/doi.org\/10.1111\/bjh.19277.","journal-title":"Br J Haematol"},{"key":"3427_CR17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/cia.s369574","volume":"18","author":"E Crickx","year":"2023","unstructured":"Crickx E, Mah\u00e9vas M, Michel M, Godeau B. Older adults and immune thrombocytopenia: considerations for the clinician. Clin Interv Aging. 2023;18:115\u201330. https:\/\/doi.org\/10.2147\/cia.s369574.","journal-title":"Clin Interv Aging"},{"key":"3427_CR18","doi-asserted-by":"publisher","first-page":"109109","DOI":"10.1016\/j.thromres.2024.109109","volume":"241","author":"A Saldanha","year":"2024","unstructured":"Saldanha A, Colella MP, Villa\u00e7a PR, Thachil J, Orsi FA. The immune thrombocytopenia paradox: should we be concerned about thrombosis in ITP? Thromb Res. 2024;241:109109. https:\/\/doi.org\/10.1016\/j.thromres.2024.109109.","journal-title":"Thromb Res"},{"key":"3427_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03472-w","author":"S Deng","year":"2025","unstructured":"Deng S, Wang B, Hu Z, Cai S, Dong L. Eltrombopag for the treatment of refractory connective tissue disease-related thrombocytopenia: a pilot study of 52 cases. Arthritis Res Ther. 2025. https:\/\/doi.org\/10.1186\/s13075-024-03472-w.","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"3427_CR20","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2100596","volume":"385","author":"CA Bradbury","year":"2021","unstructured":"Bradbury CA, Pell J, Hill Q, Bagot C, Cooper N, Ingram J, et al. Mycophenolate mofetil for first-line treatment of immune thrombocytopenia. N Engl J Med. 2021;385(10):885\u201395. https:\/\/doi.org\/10.1056\/NEJMoa2100596.","journal-title":"N Engl J Med"},{"key":"3427_CR21","doi-asserted-by":"publisher","unstructured":"Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, Cuker A, Despotovic JM, George JN, Grace RF, K\u00fchne T, Kuter DJ, Lim W, McCrae KR, Pruitt B, Shimanek H, Vesely SK. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019 Dec 10;3(23):3829-3866. https:\/\/doi.org\/10.1182\/bloodadvances.2019000966. Erratum in: Blood Adv. 2020 Jan 28;4(2):252. https:\/\/doi.org\/10.1182\/bloodadvances.2019001380. PMID: 31794604; PMCID: PMC6963252.","DOI":"10.1182\/bloodadvances.2019000966"},{"issue":"6","key":"3427_CR22","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3324\/haematol.2019.218883","volume":"104","author":"E Lucchini","year":"2019","unstructured":"Lucchini E, Zaja F, Bussel J. Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019? Haematologica. 2019;104(6):1124\u201335. https:\/\/doi.org\/10.3324\/haematol.2019.218883.","journal-title":"Haematologica"},{"key":"3427_CR23","doi-asserted-by":"publisher","first-page":"39003","DOI":"10.1038\/srep39003","volume":"6","author":"L Wang","year":"2016","unstructured":"Wang L, Gao Z, Chen XP, Zhang HY, Yang N, Wang FY, et al. Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: a systematic review and meta-analysis. Sci Rep. 2016;6:39003. https:\/\/doi.org\/10.1038\/srep39003.","journal-title":"Sci Rep"},{"key":"3427_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/tid.70012","author":"L Schumacher","year":"2025","unstructured":"Schumacher L, Philippart O, Carr A, Sadler CJC, Paluri S. Safety of once-weekly dapsone for pneumocystis jirovecii pneumonia prophylaxis in kidney transplant recipients. Transpl Infect Dis. 2025. https:\/\/doi.org\/10.1111\/tid.70012.","journal-title":"Transpl Infect Dis"},{"issue":"9","key":"3427_CR25","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.4103\/jfmpc.jfmpc_338_24","volume":"13","author":"KP Naik","year":"2024","unstructured":"Naik KP, Ganguly S, Shukla AK, Chhabra N, Prabha N, Ahmed G. Dapsone-induced haemolysis among leprosy patients on MDT from an endemic area of central India. J Fam Med Prim Care. 2024;13(9):3887\u201391. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_338_24.","journal-title":"J Fam Med Prim Care"},{"key":"3427_CR26","volume-title":"Basic and clinical pharmacology 14th edition","author":"BG Katzung","year":"2017","unstructured":"Katzung BG, Masters S, Trevor A. Basic and clinical pharmacology 14th edition. New York: McGraw-Hill Education; 2017."},{"key":"3427_CR27","volume-title":"Chronic anemia","author":"M Badireddy","year":"2025","unstructured":"Badireddy M, Baradhi KM. Chronic anemia. Treasure Island: StatPearls Publishing; 2025."},{"key":"3427_CR28","volume-title":"Goodman and Gilman\u2019s the pharmacological basis of therapeutics","author":"L Brunton","year":"2011","unstructured":"Brunton L, Chabner B, Knollmann B. Goodman and Gilman\u2019s the pharmacological basis of therapeutics. New York: McGraw-Hill; 2011."},{"key":"3427_CR29","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1182\/blood-2023-181606","volume":"142","author":"M Larue","year":"2023","unstructured":"Larue M, Moulis G, Rueter M, Audia S, Terriou L, Viallard J-F, et al. Efficacy and safety of dapsone in primary immune thrombocytopenia. Results of a randomized, placebo-controlled multicenter trial and of a single-arm, emulated trial in the prospective, multicenter Carmen-France registry. Blood. 2023;142:3983. https:\/\/doi.org\/10.1182\/blood-2023-181606.","journal-title":"Blood"},{"key":"3427_CR30","volume-title":"Biochemistry","author":"DR Ferrier","year":"2014","unstructured":"Ferrier DR. Biochemistry. Philadelphia: Lippincott Williams & Wilkins; 2014."},{"issue":"3","key":"3427_CR31","doi-asserted-by":"publisher","first-page":"102844","DOI":"10.1016\/j.rpth.2025.102844","volume":"9","author":"T Everhardt","year":"2025","unstructured":"Everhardt T, Julian K, Benefield R, Wilson A, Wilson N, Parker CJ, et al. Platelet response following dexamethasone in obese vs nonobese patients with primary, acute immune-mediated thrombocytopenia. Res Pract Thromb Haemost. 2025;9(3):102844. https:\/\/doi.org\/10.1016\/j.rpth.2025.102844.","journal-title":"Res Pract Thromb Haemost"},{"key":"3427_CR32","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2147\/CEOR.S177324","volume":"10","author":"G Tremblay","year":"2018","unstructured":"Tremblay G, Dolph M, Bhor M, Said Q, Elliott B, Briggs A. Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia. Clinicoecon Outcomes Res. 2018;10:705\u201313. https:\/\/doi.org\/10.2147\/CEOR.S177324.","journal-title":"Clinicoecon Outcomes Res"},{"key":"3427_CR33","doi-asserted-by":"publisher","first-page":"917567","DOI":"10.1155\/2015\/917567","volume":"2015","author":"R Nee","year":"2015","unstructured":"Nee R, Rivera I, Little DJ, Yuan CM, Abbott KC. Cost-utility analysis of Mycophenolate mofetil versus Azathioprine based regimens for maintenance therapy of proliferative lupus nephritis. Int J Nephrol. 2015;2015:917567. https:\/\/doi.org\/10.1155\/2015\/917567.","journal-title":"Int J Nephrol"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03427-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03427-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03427-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T11:50:22Z","timestamp":1768391422000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-025-03427-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3427"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03427-0","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}